2.4.2.17	(4E)-4-[(4-chlorophenyl)(hydroxy)methylidene]-1-(pyridin-3-ylmethyl)-5-(3,4,5-trimethoxyphenyl)pyrrolidine-2,3-dione	binds to the cavity between the domains I and II. The terminal chlorobenzoyl group of 1 makes hydrophobic interactions with the amphiphilic pocket near the phosphoribosyl pyrophosphate binding site	76506	
2.4.2.17	1,2,4-Triazole-3-alanine	-	29236	
2.4.2.17	1-(5-phospho-alpha-D-ribosyl)-ATP	product inhibition, competitive to both substrates	51101	
2.4.2.17	1-(5-phospho-beta-D-ribosyl)-ATP	product inhibition	44706	
2.4.2.17	1-[(5,6-diphenyl-1,2,4-triazin-3-yl)sulfanyl]-3-(1,3-thiazol-2-yl)propan-2-one	most potent inhibitor, spans the PR-ATP binding site, exhibits greater than 50% inhibition at 0.01 mM, 40% inhibition at 0.001 mM	39577	
2.4.2.17	2-([7-[(3-hydroxyphenyl)amino]-4-nitro-2,1,3-benzoxadiazol-5-yl]amino)-5-nitrophenol	exhibits 46% inhibition	76537	
2.4.2.17	2-([7-[(3-hydroxyphenyl)amino]-4-nitro-2,1,3-benzoxadiazol-5-yl]amino)-5-nitrophenol	has whole-cell activity at 0.012 mM	76537	
2.4.2.17	2-methyl-L-histidine	-	112427	
2.4.2.17	2-thiazol-DL-alanine	-	112455	
2.4.2.17	2-[(2-bromo-3,5-dinitrophenyl)carbonyl]-N-phenylhydrazinecarboxamide	exhibits 71% inhibition	39582